Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

Annals of the Rheumatic Diseases
L C CoatesP S Helliwell

Abstract

To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With recent therapeutic advances, this is now a goal for treatment and may represent a measure to compare therapies. It defines a satisfactory state of disease activity rather than a change, and encompasses all aspects of the disease. 40 patient profiles were sampled from an observational PsA database. Sixty experts in PsA classified these as in MDA or not. A consensus of > or =70% was accepted, identifying 13 profiles in MDA. Summary statistics created possible cut-off points for the definition. Considering the number of measures that must be met, 35 candidate definitions were created and tested using receiver operating characteristic curves (ROC) for sensitivity and specificity. Four candidate definitions showed high area under the curve values on ROC testing. Definitions with high outlying values were excluded as they were not considered to represent MDA. Aiming for high specificity to reduce false positives resulted in a preference for the following definition: "A patient is classified as achieving MDA when meeting 5 of the 7 following criteria: tender joint count < or =1; swollen joint count < or =1; Psoriasis Activity and Severity Index < or ...Continue Reading

Citations

Jan 16, 2013·International Journal of Rheumatology·Priscilla C H WongLai-Shan Tam
Feb 1, 2011·Therapeutic Advances in Musculoskeletal Disease·Tajvur P SaberDouglas J Veale
Jan 6, 2011·Arthritis Research & Therapy·Andrew Barr, Andrew Keat
Jun 7, 2013·Annals of the Rheumatic Diseases·Rusmir HusicChristian Dejaco
Mar 14, 2014·Current Rheumatology Reports·William TillettNeil McHugh
Jul 9, 2014·Nature Reviews. Rheumatology·Ignazio OlivieriAngela Padula
May 14, 2014·Clinical Rheumatology·M L Acosta FelquerE R Soriano
Mar 29, 2014·Actas dermo-sifiliográficas·A López-Ferrer, A Laiz-Alonso
Dec 10, 2014·Best Practice & Research. Clinical Rheumatology·Enrique Roberto SorianoLiron Caplan
Dec 10, 2014·Best Practice & Research. Clinical Rheumatology·Pedro M Machado, Siba P Raychaudhuri
May 31, 2012·Current Rheumatology Reports·William Tillett, Neil McHugh
Nov 18, 2015·Expert Opinion on Biological Therapy·Tristan Boyd, A Kavanaugh
Jan 7, 2011·Expert Opinion on Drug Safety·Amr A SaadDarren M Ashcroft
Jan 26, 2016·Expert Review of Clinical Immunology·V Chandran, A B Maharaj
Jul 29, 2011·Reumatología clinica·Jose Luis Fernández SueiroUNKNOWN Sociedad Española de Reumatología [Spanish Society of Rheumatology]
Oct 18, 2015·Rheumatic Diseases Clinics of North America·Laura Coates
Apr 14, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·P LawsR B Warren
May 3, 2016·Rheumatic Diseases Clinics of North America·Ana-Maria Orbai, Alexis Ogdie
Jul 1, 2010·Arthritis Care & Research·Laura C Coates, Philip S Helliwell
Dec 17, 2015·Annals of the Rheumatic Diseases·Laura C Coates, Philip S Helliwell
Oct 5, 2015·Lancet·Dafna D Gladman
May 31, 2015·Autoimmunity Reviews·Ennio LubranoPiercarlo Sarzi-Puttini
Feb 20, 2014·The Journal of Dermatological Treatment·G GirolomoniC Paul
Jun 5, 2013·Seminars in Arthritis and Rheumatism·Lazaros I SakkasMarianna Vlychou
Aug 5, 2016·Expert Review of Clinical Immunology·Ashish J MathewPhilip G Conaghan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.